BR112018071705A2 - método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i) - Google Patents

método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i)

Info

Publication number
BR112018071705A2
BR112018071705A2 BR112018071705-3A BR112018071705A BR112018071705A2 BR 112018071705 A2 BR112018071705 A2 BR 112018071705A2 BR 112018071705 A BR112018071705 A BR 112018071705A BR 112018071705 A2 BR112018071705 A2 BR 112018071705A2
Authority
BR
Brazil
Prior art keywords
formula
compound
nafld
nash
ash
Prior art date
Application number
BR112018071705-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Scwu Edwin
J.S. Chiu Peter
Mei-Chi Hsu May
Original Assignee
Taiwanj Pharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwanj Pharmaceuticals Co., Ltd. filed Critical Taiwanj Pharmaceuticals Co., Ltd.
Publication of BR112018071705A2 publication Critical patent/BR112018071705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018071705-3A 2016-04-22 2017-04-20 método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i) BR112018071705A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
USUS62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
USUS62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
BR112018071705A2 true BR112018071705A2 (pt) 2019-02-19

Family

ID=58668969

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071705-3A BR112018071705A2 (pt) 2016-04-22 2017-04-20 método de profilaxia ou tratamento de nafld, nash ou ash, uso de um composto de fórmula (i), e composto de fórmula (i)

Country Status (10)

Country Link
US (1) US10045977B2 (enExample)
EP (1) EP3445363A1 (enExample)
JP (1) JP2019514872A (enExample)
KR (1) KR20180129909A (enExample)
CN (2) CN109069503A (enExample)
AU (1) AU2017253228B2 (enExample)
BR (1) BR112018071705A2 (enExample)
CA (1) CA3021788C (enExample)
RU (1) RU2717677C1 (enExample)
WO (1) WO2017184819A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
ES2860423T3 (es) 2014-05-28 2021-10-05 Childrens Hospital Med Ct Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
US20190247373A1 (en) * 2016-07-14 2019-08-15 Children's Hospital Medical Center Methods for treating fibrosis
SG10202104575WA (en) 2016-11-04 2021-06-29 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
CA3045145A1 (en) 2016-12-05 2018-06-14 Children's Hospital Medical Center Colonic organoids and methods of making and using same
US12281334B2 (en) 2017-04-14 2025-04-22 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
WO2019074793A1 (en) 2017-10-10 2019-04-18 Children's Hospital Medical Center OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME
US12379372B2 (en) 2017-12-21 2025-08-05 Children's Hospital Medical Center Digitalized human organoids and methods of using same
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
CN112823012A (zh) 2018-09-12 2021-05-18 儿童医院医学中心 用于产生造血干细胞及其衍生物的类器官组合物
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
US12534709B2 (en) 2019-05-31 2026-01-27 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CA3141807A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Methods of generating and expanding hematopoietic stem cells
KR20230073128A (ko) 2021-11-18 2023-05-25 (주)인벤티지랩 날트렉손을 포함하는 서방성 주사용 조성물 및 이의 제조 방법
WO2023090922A1 (ko) 2021-11-18 2023-05-25 (주)인벤티지랩 날트렉손을 포함하는 서방성 주사용 조성물 및 이의 제조 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
WO2003097608A2 (en) 2002-05-17 2003-11-27 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US10363251B2 (en) * 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
CN102048733B (zh) * 2010-12-23 2011-12-28 武汉同源药业有限公司 盐酸纳美芬在制备治疗脂肪肝的药物中的用途
UA114360C2 (uk) * 2013-04-22 2017-05-25 Каділа Хелткере Лімітед Спосіб лікування та/або зменшення інтенсивності неалкогольної жирової хвороби печінки (нжхп)
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response

Also Published As

Publication number Publication date
KR20180129909A (ko) 2018-12-05
AU2017253228A8 (en) 2019-01-17
US10045977B2 (en) 2018-08-14
CA3021788C (en) 2021-08-03
RU2717677C1 (ru) 2020-03-25
CN117137917A (zh) 2023-12-01
CA3021788A1 (en) 2017-10-26
AU2017253228B2 (en) 2020-04-09
WO2017184819A1 (en) 2017-10-26
EP3445363A1 (en) 2019-02-27
JP2019514872A (ja) 2019-06-06
CN109069503A (zh) 2018-12-21
AU2017253228A1 (en) 2018-09-27
US20170304294A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
IL263947B (en) Compositions and methods for making benzylisoquinoline alkaloids, morphinan alkaloids, thebaine, and derivatives thereof
NZ733174A (en) Quinazoline derivatives used to treat hiv
NZ733125A (en) Isoquinoline compounds for the treatment of hiv
MX391812B (es) Agonista fxr derivado de esteroides.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
EP4306168A3 (en) Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
EA201692095A1 (ru) Имидазо[4,5-c]хинолин-2-оновые соединения и их применение в лечении рака
BR112017002811A2 (pt) compostos de pirrolopirimidina usados como agonista de tlr7
MY197673A (en) Combination comprising ep4 antagonist and immune checkpoint inhibitor
NZ733135A (en) Fused pyrimidine compounds for the treatment of hiv
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres
MX2019015524A (es) Composiciones inmunogenicas.
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
TN2015000542A1 (en) Novel compounds for the treatment of cancer
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
PH12017501122A1 (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
BR112016008704A8 (pt) derivados de indol-urea glucopiranosil-substituídos, composições farmacêuticas, e seus usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2622 DE 06/04/2021.

B350 Update of information on the portal [chapter 15.35 patent gazette]